Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.

Fiche publication


Date publication

février 2020

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi


Tous les auteurs :
André T, Vernerey D, Im SA, Bodoky G, Buzzoni R, Reingold S, Rivera F, McKendrick J, Scheithauer W, Ravit G, Fountzilas G, Yong WP, Isaacs R, Österlund P, Liang JT, Creemers GJ, Rakez M, Van Cutsem E, Cunningham D, Tabernero J, de Gramont A

Résumé

The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its primary end point of improving disease-free survival (DFS) with the addition of bevacizumab to oxaliplatin-based chemotherapy in stage III colon cancer (CC). We report here the long-term survival results (S-AVANT).

Mots clés

FOLFOX, XELOX, adjuvant, bevacizumab, colon cancer

Référence

Ann. Oncol.. 2020 Feb;31(2):246-256